Stock Scorecard
Stock Summary for XBiotech Inc (XBIT) - $2.56 as of 12/11/2025 6:13:56 PM EST
Total Score
13 out of 30
Safety Score
17 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for XBIT
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for XBIT
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for XBIT
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for XBIT
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for XBIT (17 out of 100)
| Stock Price Rating (Max of 10) | 3 |
| Historical Stock Price Rating (Max of 10) | 5 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 4 |
| Book Value to Price (Max of 10) | 10 |
| Analyst Buy Ratings (Max of 5) | 0 |
| Analyst Strong Buy Ratings (Max of 5) | 0 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 4 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | -10 |
Latest News for for XBIT
Financial Details for XBIT
Company Overview |
|
|---|---|
| Ticker | XBIT |
| Company Name | XBiotech Inc |
| Country | N/A |
| Description | XBiotech Inc. is a transformative biopharmaceutical company based in Austin, Texas, specializing in the development of True Human monoclonal antibodies aimed at treating a range of diseases. Leveraging advanced technology to utilize human immune cells, the company seeks to create innovative and safer therapeutic options. With a diverse and promising pipeline, XBiotech is strategically positioned as a frontrunner in the biotherapeutics arena, committed to enhancing patient care and addressing significant unmet medical needs across multiple therapeutic areas. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 2.56 |
| Price 4 Years Ago | 11.13 |
| Last Day Price Updated | 12/11/2025 6:13:56 PM EST |
| Last Day Volume | 113,048 |
| Average Daily Volume | 155,545 |
| 52-Week High | 7.24 |
| 52-Week Low | 2.09 |
| Last Price to 52 Week Low | 22.49% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 23.88 |
| Sector PE | 108.41 |
| 5-Year Average PE | -10.80 |
| Free Cash Flow Ratio | 0.53 |
| Industry Free Cash Flow Ratio | 12.23 |
| Sector Free Cash Flow Ratio | 30.42 |
| Current Ratio Most Recent Quarter | 41.78 |
| Total Cash Per Share | 4.83 |
| Book Value Per Share Most Recent Quarter | 5.48 |
| Price to Book Ratio | 0.45 |
| Industry Price to Book Ratio | 48.45 |
| Sector Price to Book Ratio | 46.89 |
| Price to Sales Ratio Twelve Trailing Months | 12.23 |
| Industry Price to Sales Ratio Twelve Trailing Months | 20.95 |
| Sector Price to Sales Ratio Twelve Trailing Months | 14.02 |
| Analyst Buy Ratings | N/A |
| Analyst Strong Buy Ratings | N/A |
Share Statistics |
|
| Total Shares Outstanding | 30,487,700 |
| Market Capitalization | 78,048,512 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | 7/15/2021 |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 2.4700 |
| Total Years Dividend Increasing | 0 |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 1 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -56.90% |
| Reported EPS 12 Trailing Months | -0.95 |
| Reported EPS Past Year | -0.61 |
| Reported EPS Prior Year | -1.26 |
| Net Income Twelve Trailing Months | -29,156,000 |
| Net Income Past Year | -38,531,000 |
| Net Income Prior Year | -24,557,000 |
| Quarterly Revenue Growth YOY | -93.30% |
| 5-Year Revenue Growth | -100.00% |
| Operating Margin Twelve Trailing Months | 0.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 147,367,000 |
| Total Cash Past Year | 172,677,000 |
| Total Cash Prior Year | 200,023,000 |
| Net Cash Position Most Recent Quarter | 137,367,000 |
| Net Cash Position Past Year | 172,677,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 10,000,000 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 0.94 |
| Total Stockholder Equity Past Year | 182,268,000 |
| Total Stockholder Equity Prior Year | 218,846,000 |
| Total Stockholder Equity Most Recent Quarter | 167,080,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -23,847,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -0.78 |
| Free Cash Flow Past Year | -32,267,000 |
| Free Cash Flow Prior Year | -19,087,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | None |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.03 |
| MACD Signal | -0.04 |
| 20-Day Bollinger Lower Band | 2.14 |
| 20-Day Bollinger Middle Band | 2.69 |
| 20-Day Bollinger Upper Band | 3.25 |
| Beta | 0.77 |
| RSI | 55.80 |
| 50-Day SMA | 3.04 |
| 150-Day SMA | 4.71 |
| 200-Day SMA | 4.95 |
System |
|
| Modified | 12/11/2025 11:38:35 AM EST |